Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.5% objective response rate, including a complete response   San Diego, CA, and Calgary, AB – November 9, 2023 – Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) (Oncolytics), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of positive, interim results from the Phase […]